Glycated albumin in diabetic patients with chronic kidney disease

Clinica Chimica Acta

Volumn 413, Issue 19-20, 2012, Pages 1555-1561

  Zheng, Cai Mei ^a   Ma, Wen Ya ^b   Wu, Chia Chao ^c   Lu, Kuo Cheng ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Amadori reaction; Chronic kidney disease; Diabetes; Glycated albumin; Glycated hemoglobin

Indexed keywords

ALBUMIN; FRUCTOSAMINE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C;

AMADORI REARRANGEMENT; BINDING SITE; BLOOD GLUCOSE MONITORING; BONE METABOLISM; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIAGNOSTIC VALUE; DIALYSIS; DRUG PROTEIN BINDING; GLYCEMIC CONTROL; GLYCEMIC INDEX; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN GLYCOSYLATION; REVIEW; SCREENING;

ANEMIA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD TRANSFUSION; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; FRUCTOSAMINE; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; RENAL INSUFFICIENCY, CHRONIC; SERUM ALBUMIN;

EID: 84864383134     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.04.025     Document Type: Review

References (93)

1. Cho S.J., Roman G., Yeboah F., Konishi Y. The road to advanced glycation end products: a mechanistic perspective. Curr Med Chem 2007, 14:1653-1671.
2. Horvat S., Jakas A. Peptide and amino acid glycation: new insights into the Maillard reaction. J Pept Sci 2004, 10:119-137.
3. Mosca A., Carenini A., Zoppi F., et al. Plasma protein glycation as measured by fructosamine assay. Clin Chem 1987, 33:1141-1146.
4. Garlick R.L., Mazer J.S. The principal site of nonenzymatic glycosylation of human serum albumin in vivo. J Biol Chem 1983, 258:6142-6146.
5. Iberg N., Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J Biol Chem 1986, 261:13542-13545.
6. Kisugi R., Kouzuma T., Yamamoto T., et al. Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin. Clin Chim Acta 2007, 382:59-64.
7. Koyama H., Sugioka N., Uno A., Mori S., Nakajima K. Effects of glycosylation of hypoglycaemic drug binding to serum albumin. Biopharm Drug Dispos 1997, 18:791-801.
8. Sudlow G., Birkett D.J., Wade D.N. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol 1976, 12:1052-1061.
9. Ascoli G.A., Domenici E., Bertucci C. Drug binding to human serum albumin: abridged review of results obtained with high-performance liquid chromatography and circular dichroism. Chirality 2006, 18:667-679.
10. Joseph K.S., Anguizola J., Jackson A.J., Hage D.S. Chromatographic analysis of acetohexamide binding to glycated human serum albumin. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:2775-2781.
11. Joseph K.S., Anguizola J., Hage D.S. Binding of tolbutamide to glycated human serum albumin. J Pharm Biomed Anal 2011, 54:426-432.
12. Matsuda R., Anguizola J., Joseph K.S., Hage D.S. High-performance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albumin. Anal Bioanal Chem 2011, 401:2811-2819.
13. Reed P., Bhatnagar D., Dhar H., Winocour P.H. Precise measurement of glycated serum albumin by column affinity chromatography and immunoturbidimetry. Clin Chim Acta 1986, 161:191-199.
14. Day J.F., Thorpe S.R., Baynes J.W. Nonenzymatically glucosylated albumin. In vitro preparation and isolation from normal human serum. J Biol Chem 1979, 254:595-597.
15. Yasukawa K., Abe F., Shida N., et al. High-performance affinity chromatography system for the rapid, efficient assay of glycated albumin. J Chromatogr 1992, 597:271-275.
16. Guthrow C.E., Morris M.A., Day J.F., Thorpe S.R., Baynes J.W. Enhanced nonenzymatic glucosylation of human serum albumin in diabetes mellitus. Proc Natl Acad Sci U S A 1979, 76:4258-4261.
17. Kouzuma T., Uemastu Y., Usami T., Imamura S. Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method. Clin Chim Acta 2004, 346:135-143.
18. Ohe Y., Matsuura M., Nakajima Y., et al. Radioimmunoassay of glycosylated albumin with monoclonal antibody to glucitol-lysine. Clin Chim Acta 1987, 169:229-238.
19. Ikeda K., Sakamoto Y., Kawasaki Y., et al. Determination of glycated albumin by enzyme-linked boronate immunoassay (ELBIA). Clin Chem 1998, 44:256-263.
20. Furusyo N., Koga T., Ai M., et al. Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia 2011, 54:3028-3036.
21. Nathan D.M., Steffes M.W., Sun W., Rynders G.P., Lachin J.M. Determining stability of stored samples retrospectively: the validation of glycated albumin. Clin Chem 2011, 57:286-290.
22. Hiramatsu Y., Shimizu I., Omori Y., Nakabayashi M. Determination of reference intervals of glycated albumin and hemoglobin A1c in healthy pregnant Japanese women and analysis of their time courses and influencing factors during pregnancy. Endocr J 2012, 59:145-151.
23. Kawazu S., Tomono S., Shimizu M., et al. The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus. The effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study. J Diabetes Complications 1994, 8:13-17.
24. Hovind P., Rossing P., Tarnow L., Smidt U.M., Parving H.H. Progression of diabetic nephropathy. Kidney Int 2001, 59:702-709.
25. McMurray S.D., Johnson G., Davis S., McDougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 2002, 40:566-575.
26. Mak R.H. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 1992, 41:1049-1054.
27. Shrishrimal K., Hart P., Michota F. Managing diabetes in hemodialysis patients: observations and recommendations. Cleve Clin J Med 2009, 76:649-655.
28. Mak R.H. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000, 13:4-8.
29. Gerich J.E., Meyer C., Woerle H.J., Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001, 24:382-391.
30. Abe M., Kikuchi F., Kaizu K., Matsumoto K. The influence of hemodialysis membranes on the plasma insulin level of diabetic patients on maintenance hemodialysis. Clin Nephrol 2008, 69:354-360.
31. Bunn H.F., Haney D.N., Kamin S., Gabbay K.H., Gallop P.M. The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J Clin Invest 1976, 57:1652-1659.
32. Lee E.Y., Lee B.W., Kim D., et al. Glycated albumin is a useful glycation index for monitoring fluctuating and poorly controlled type 2 diabetic patients. Acta Diabetol 2011, 48:167-172.
33. Mittman N., Desiraju B., Fazil I., et al. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Kidney Int 2010, S41-S45.
34. Borg R., Kuenen J.C., Carstensen B., et al. HbA(c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study. Diabetologia 2011, 54:69-72.
35. Little R.R., Rohlfing C.L., Wiedmeyer H.-M., et al. The National Glycohemoglobin Standardization Program: a five-year progress report. Clin Chem 2001, 47:1985-1992.
36. ADA Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33:S62-S69.
37. Goldstein D.E., Little R.R., Lorenz R.A., et al. Tests of glycemia in diabetes. Diabetes Care 1995, 18:896-909.
38. Kim C., Bullard K.M., Herman W.H., Beckles G.L. Association between iron deficiency and A1C Levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care 2010, 33:780-785.
39. Hashimoto K., Noguchi S., Morimoto Y., et al. A1C but not serum glycated albumin is elevated in late pregnancy owing to iron deficiency. Diabetes Care 2008, 31:1945-1948.
40. Panzer S., Graninger W., Kronik G., Bettelheim P., Lechner K. Glycosylated hemoglobin as a long-term parameter in appraising the severity of hemolytic disease. Klin Wochenschr 1983, 61:839-843.
41. Kutter D., Thoma J. Hereditary spherocytosis and other hemolytic anomalies distort diabetic control by glycated hemoglobin. Clin Lab 2006, 52:477-481.
42. Bosman D.R., Winkler A.S., Marsden J.T., Macdougall I.C., Watkins P.J. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001, 24:495-499.
43. Bry L., Chen P.C., Sacks D.B. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001, 47:153-163.
44. Vos F.E., Schollum J.B., Coulter C.V., et al. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. Nephrology (Carlton) 2012, 17:182-188.
45. Ly J., Marticorena R., Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis 2004, 44:715-719.
46. Vos F.E., Schollum J.B., Coulter C.V., et al. Red blood cell survival in long-term dialysis patients. Am J Kidney Dis 2011, 58:591-598.
47. Koga M., Murai J., Saito H., Kasayama S. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes. Diabetes Care 2010, 33:270-272.
48. Inaba M., Okuno S., Kumeda Y., et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007, 18:896-903.
49. Ng J.M., Jennings P.E., Laboi P., Jayagopal V. Erythropoetin treatment significantly alters measured glycated haemoglobin (HbA1c). Diabet Med 2008, 25:239-240.
50. Ng J.M., Cooke M., Bhandari S., Atkin S.L., Kilpatrick E.S. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care 2010, 33:2310-2313.
51. Weykamp C.W., Penders T.J., Siebelder C.W., Muskiet F.A., van der Slik W. Interference of carbamylated and acetylated hemoglobins in assays of glycohemoglobin by HPLC, electrophoresis, affinity chromatography, and enzyme immunoassay. Clin Chem 1993, 39:138-142.
52. Fluckiger R., Harmon W., Meier W., Loo S., Gabbay K.H. Hemoglobin carbamylation in uremia. N Engl J Med 1981, 304:823-827.
53. Armbruster D.A. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 1987, 33:2153-2163.
54. Schleicher E.D., Olgemoller B., Wiedenmann E., Gerbitz K.D. Specific glycation of albumin depends on its half-life. Clin Chem 1993, 39:625-628.
55. Goldstein D.E., Little R.R., Lorenz R.A., et al. Tests of glycemia in diabetes. Diabetes Care 2004, 27:1761-1773.
56. Lamb E., Venton T.R., Cattell W.R., Dawnay A. Serum glycated albumin and fructosamine in renal dialysis patients. Nephron 1993, 64:82-88.
57. Coronel F., Macia M., Cidoncha A., et al. Fructosamine levels in CAPD: its value as glycemic index. Adv Perit Dial 1991, 7:253-256.
58. Browner W.S., Pressman A.R., Lui L.Y., Cummings S.R. Association between serum fructosamine and mortality in elderly women: the study of osteoporotic fractures. Am J Epidemiol 1999, 149:471-475.
59. Peacock T.P., Shihabi Z.K., Bleyer A.J., et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008, 73:1062-1068.
60. Okada T., Nakao T., Matsumoto H., et al. Influence of age and nutritional status on glycated albumin values in hemodialysis patients. Intern Med 2009, 48:1495-1499.
61. Koga M., Murai J., Saito H., Matsumoto S., Kasayama S. Effects of thyroid hormone on serum glycated albumin levels: study on non-diabetic subjects. Diabetes Res Clin Pract 2009, 84:163-167.
62. Koga M., Kasayama S., Kanehara H., Bando Y. CLD (chronic liver diseases)-HbA1C as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver diseases. Diabetes Res Clin Pract 2008, 81:258-262.
63. Okada T., Nakao T., Matsumoto H., et al. Influence of proteinuria on glycated albumin values in diabetic patients with chronic kidney disease. Intern Med 2011, 50:23-29.
64. Freedman B.I., Shenoy R.N., Planer J.A., et al. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int 2010, 30:72-79.
65. Yoshiuchi K., Matsuhisa M., Katakami N., et al. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J 2008, 55:503-507.
66. Koga M., Murai J., Saito H., et al. Glycated albumin levels are higher relative to glycated haemoglobin levels in gastrectomized subjects. Ann Clin Biochem 2010, 47:39-43.
67. Yamada S., Inaba M., Shidara K., et al. Association of glycated albumin, but not glycated hemoglobin, with peripheral vascular calcification in hemodialysis patients with type 2 diabetes. Life Sci 2008, 83:516-519.
68. Cohen G., Rudnicki M., Walter F., Niwa T., Horl W.H. Glucose-modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytes. J Am Soc Nephrol 2001, 12:1264-1271.
69. Rondeau P., Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie 2011, 93:645-658.
70. de Souza Pinto R., Castilho G., Paim B.A., et al. Inhibition of macrophage oxidative stress prevents the reduction of ABCA-1 transporter induced by advanced glycated albumin. Lipids 2012, 47:443-450.
71. Bala K., Gomes J., Gohil N.K. Interaction of glycated human serum albumin with endothelial cells in a hemodynamic environment: structural and functional correlates. Mol Biosyst 2011, 7:3036-3041.
72. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol 2008, 45:1-16.
73. Lu L., Pu L.J., Xu X.W., et al. Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-alpha with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. Clin Biochem 2007, 40:810-816.
74. Pu L.J., Lu L., Shen W.F., et al. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ J 2007, 71:1067-1073.
75. Tahara Y. Analysis of the method for conversion between levels of HbA1c and glycated albumin by linear regression analysis using a measurement error model. Diabetes Res Clin Pract 2009, 84:224-229.
76. Okada T., Nakao T., Matsumoto H., et al. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med 2007, 46:807-814.
77. Fukuoka K., Nakao K., Morimoto H., et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton) 2008, 13:278-283.
78. Williams M.E., Lacson E., Teng M., Ofsthun N., Lazarus J.M. Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006, 70:1503-1509.
79. Freedman B.I., Andries L., Shihabi Z.K., et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011, 6:1635-1643.
80. Kalantar-Zadeh K., Kopple J.D., Regidor D.L., et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007, 30:1049-1055.
81. Li Q., Pan J.M., Ma X.J., et al. Combined utility of hemoglobin A1c and glycated albumin in diabetic screening. Zhonghua Yi Xue Za Zhi 2011, 91:1813-1816.
82. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 2007, 18:427-444.
83. Terada M., Inaba M., Yano Y., et al. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone 1998, 22:17-23.
84. Yoshida O., Inaba M., Terada M., et al. Impaired response of human osteosarcoma (MG-63) cells to human parathyroid hormone induced by sustained exposure to high glucose. Miner Electrolyte Metab 1995, 21:201-204.
85. Inaba M., Terada M., Koyama H., et al. Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res 1995, 10:1050-1056.
86. Yamada S., Inaba M., Okada S., et al. Association of glycated albumin, but not glycated hemoglobin, with calcaneus quantitative ultrasound in male hemodialysis patients with type 2 diabetes mellitus. Metabolism 2010, 59:390-394.
87. McCullough P.A. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008, 51:1419-1428.
88. Pflueger A., Abramowitz D., Calvin A.D. Role of oxidative stress in contrast-induced acute kidney injury in diabetes mellitus. Med Sci Monit 2009, 15:RA125-RA136.
89. Cronin R.E. Contrast-induced nephropathy: pathogenesis and prevention. Pediatr Nephrol 2010, 25:191-204.
90. Heyman S.N., Rosen S., Khamaisi M., Idee J.M., Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest Radiol 2010, 45:188-195.
91. Ziyadeh F.N., Cohen M.P. Effects of glycated albumin on mesangial cells: evidence for a role in diabetic nephropathy. Mol Cell Biochem 1993, 125:19-25.
92. Ma W.-Y., Wu C.-C., Pei D., et al. Glycated albumin is independently associated with estimated glomerular filtration rate in nondiabetic patients with chronic kidney disease. Clin Chim Acta 2011, 412:583-586.
93. Ding F.H., Lu L., Zhang R.Y., et al. Impact of elevated serum glycated albumin levels on contrast-induced acute kidney injury in diabetic patients with moderate to severe renal insufficiency undergoing coronary angiography. Int J Cardiol 2012, [Epub ahead of print].